According to the deep-dive market assessment study conducted by Growth+ Reports, the global biosimulation market was pegged at ~US$ 2.11 billion in 2020. The market is expected to witness a CAGR of ~15.5% from 2021 to 2031.

As the incidence of infectious and chronic diseases is rising, the need for drugs that can help in treating or managing these diseases is increasing. Pharmaceutical companies are constantly conducting research for developing new drugs. Biosimulation software is used for testing the toxicity, efficacy as well as safety of the drugs during development process. Moreover, increasing number of off-patent drugs has led to the rising demand for biosimilars and this is also driving the demand for biosimulation software which are used in simulation studies for biosimilars. The prominent players in the biosimulation market are focused on developing and launching new software in the market.

To access the Sample PDF of this research study, please request here: https://growthplusreports.com/inquiry/request-sample/biosimulation-market/7621

Some of the prominent players operating in the global Biosimulation Market include

• Certara
• Dassault Systemes
• Chemical Computing Group ULC
• Simulations Plus
• Rosa & Co. LLC
• Genedata AG
• Schrodinger
• Physiomics Plc
• Inosim Software GmbH
• LeadInvent Pharma
• among others